Ray Jupp is a Venture Partner at SV and CSO of Mestag, a company founded and seed funded by SV in 2020. He joined the SV Venture Partner Program in September 2020.
Prior to joining SV as a Venture Partner, Ray was the founding CSO of TrexBio, an SV founded company focused on tissue Tregs before joining Enara Bio, an SV founded company, as CSO in late 2018 as CSO and Mestag in late 2020.
Prior to his move into Biotech, Ray was head of the Immunology/Inflammation Therapeutic Area at UCB having joined in 2012. In this role he drove multiple compounds into development and through Phase 1 and 2.
Ray developed his interest in immunology having joined Roche in 1993 and set up a lab to discover novel anti-viral medicines. Ray contributed to Invirase, the first medicine developed against the proteinase encoded by HIV. He began his work on inflammatory/auto-immune diseases whilst at Rhone-Poulenc Rorer before returning to the USA to head up Inflammation Biology for Aventis. Following the creation of Sanofi, he was appointed Head of Internal Medicine, extending his disease scope to include anti-fibrotics and infectious diseases moving over 10 compounds into development, several in collaboration with Regeneron.
PhD in Biochemistry from Cardiff University, followed by a post-doctoral fellowship at the Scripps Research Institute, San Diego.